http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114344305-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a03c8620f4dee29acbad9dab004b836f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2022-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02cbb5b5d81bf8adfec71608fbe2372b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5d6528df16d2c4b77a23c3371d098f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16b627f1fe8f8a62fb1c6139939896cc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78d953260551aa32303a08c292087a2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14e1ed89bcad2ec139e96b3fea4d3fbb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a64cce5eb9dba632463eaa8c45dfd89 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_001c1dd04d881d8b54199bf7da338e37 |
| publicationDate | 2022-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114344305-A |
| titleOfInvention | Application of CDK7 inhibitor THZ1 in radiotherapy-resistant nasopharyngeal carcinoma |
| abstract | The invention relates to the field of biotechnology, in particular to the application of CDK7 inhibitor THZ1 in radiotherapy resistance treatment of nasopharyngeal carcinoma. The present invention firstly explores the differences in the phosphorylation levels of RNA polymerase II C-terminal repeat domain S5 in radiotherapy-resistant and radiosensitive cells of nasopharyngeal carcinoma, as well as after they are irradiated with radiotherapy. The CDK7-targeted inhibitor THZ1 was used to detect the drug sensitivity of radiotherapy-resistant and sensitive cells in nasopharyngeal carcinoma. To investigate whether THZ1 can increase radiosensitivity by combining THZ1 with radiotherapy on radiotherapy-resistant cells. THZ1 was applied to the radiation-resistant mouse model to explore the therapeutic effect of THZ1 on radiation-resistant tumors. The CDK7 inhibitor THZ1 in the present invention can effectively inhibit the growth of nasopharyngeal carcinoma radiotherapy-resistant tumor in the cell experiment at the in vitro level and the subcutaneous tumor formation experiment in nude mice at the in vivo level. From the cellular level and animal level, it is confirmed that THZ1 can increase the radiosensitivity when used in combination with radiotherapy, indicating that THZ1 is feasible for the treatment of radiotherapy resistance in nasopharyngeal carcinoma. |
| priorityDate | 2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 160.